The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast Cancer

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Treatment strategies for HER2+ metastatic breast cancerПодробнее

Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast CancerПодробнее

Sequencing novel HER2-targeted therapies in metastatic breast cancerПодробнее

PRECIOUS: pertuzumab retreatment in patients with HER+ breast cancerПодробнее

Frontline Pertuzumab for Metastatic Breast CancerПодробнее

Current Treatment Options for Patients With HER2-Positive Metastatic Breast CancerПодробнее

Pertuzumab, trastuzumab and cyclophosphamide in older patients with HER2+ breast cancerПодробнее

Dr. Osborne on Pertuzumab in HER2+ Breast CancerПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

First-Line Treatment of HER2-Positive Metastatic Breast CancerПодробнее

Dr. Mittendorf on the Impact of Pertuzumab in HER2+ Breast CancerПодробнее

Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast CancerПодробнее

Dr. Kolberg on Cost-Effectiveness of Pertuzumab in HER2-Positive Breast CancerПодробнее

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее

Dr. Mark Pegram on Combining Trastuzumab and PertuzumabПодробнее

Dr. Yee on Neoadjuvant Pertuzumab in HER2-Positive Breast CancerПодробнее

Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast CancerПодробнее

Paclitaxel With Pertuzumab Plus Trastuzumab in Metastatic Breast CancerПодробнее